AMP Working Group: Molecular Testing for Measurable Residual Disease Testing in Acute Myeloid Leukemia

Working Group Moderator(s)

• 

  Rena Xian, MD (she/her/hers)

  Associate Professor
  Johns Hopkins University School of Medicine
  Baltimore, Maryland, United States

Description: This session will provide updates from the AMP Clinical Practice Committee’s Working Group on molecular testing strategies for measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML). Attendees will gain insights into current efforts to standardize and improve molecular MRD assessment in clinical practice. Project progress updates will be provided in this session, along with the opportunity to provide feedback to inform the upcoming publication.

Learning Objectives:
- Evaluate relevant biomarkers and molecular test platforms used in AML MRD monitoring.
- Identify key technical and quality control considerations in molecular testing.
- Review clinical practice algorithms for implementing MRD monitoring in AML.

Presentations:

• 2:30 PM - 3:30 PM EST

  AMP Working Group: Molecular Testing for Measurable Residual Disease Testing in Acute Myeloid Leukemia
  

  Working Group Speaker: Keyur P. Patel, MD PhD – University of Texas MD Anderson Cancer Center

  Working Group Panelist: Noah Brown, MD – University of Michgian

  Working Group Panelist: Rashmi Goswami, MD, PhD (she/her/hers) – University of Toronto